🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-524805-34-00
Authorised Phase I

A dose escalation and expansion study of XB010 as a single agent and combination therapy in subjects with locally advanced or metastatic solid tumors

2025-524805-34-00 · tracked via the Priya Life Science EU tracker
Sponsor
Exelixis Inc.
Sponsor type
Pharmaceutical company
Therapeutic area
Neoplasms
Decision date
11/08/2026
Enrollment target
40
Sites
Italy, Netherlands, France, Spain

Condition studied

Locally Advanced or Metastatic Solid Tumors

Eligibility

Age group
18-64 years, 65+ years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-524805-34-00 on CTIS ↗ ← All trials in the EU